Can Cui, Ph.D., J.D.

• A biopharmaceutical company with its R&D center in the SF Bay Area: global patent portfolio management.
• A biotechnology company leveraging its proprietary human trophoblast stem cell platform—originating from a unique 2003 isolation—to provide scalable, immune‑privileged starting materials and engineered cell platforms that accelerate therapeutic research and product development: general corporate, IP, and international business development (BD) and joint venture transactions.
• A science‑based health care communications company that combines strategic insight, scientific expertise, creativity, and commercial acumen to bridge knowledge gaps and improve patient outcomes: cross-border investment and collaboration transactions.
• ARTBIO: multiple strategic transactions, including:
  • exclusive strategic collaboration with AlphaGen Therapeutics;°
  • strategic manufacturing and supply agreement with Eckert & Ziegler Strahlen- und Medizintechnik AG;°
  • new partnership agreement with SpectronRx;° and
  • manufacturing and supply agreement with PharmaLogic Holdings Corp.°
• A new drug development company focusing on the nervous system, headquartered in Shanghai, China with wholly-owned subsidiaries in Beijing and Chongqing, China, New York, NY, and Sydney, Australia: global patent portfolio management, BD transactions, financing, and IP dispute resolution.
• Multiple leading gene editing drug innovation companies in China: general corporate, IP, financing and various BD and licensing transactions, including Base Therapeutics’ out-licensing of its proprietary base editing technology to an internationally leading multinational biopharmaceutical company.
• A pioneering biotechnology company in mucosal RNA therapeutics: in-licensing of user-friendly, cutting-edge enzyme solutions for mRNA research from an innovative company based in Madison, WI.
• A company focusing on the research and development, promotion and application of Plasmodium-based anti-cancer technology system: IP, financing, FDA regulatory, and U.S. capital markets matters.
• An innovative technology company focusing on nucleic acid process development and application: IP opinions.
• A company with a mission to treat Graft Versus Host Disease through a pioneering CAR-T cell therapy: general corporate and financing matters.
• A specialty CRO offering bioassay consulting, development, validation, and sample testing services: general corporate matters.
• A biotech company based in Menlo Park, CA that focuses on the discovery and development of transformational therapeutics to combat life-threatening diseases, especially cancer: international trade matter and BD transactions.
• An immunotherapy company dedicated to the development of innovative therapeutics based on T-cell receptors: general IP, labor and employment, FDA regulatory, services and technology transactions matters, including the in-licensing of T-cell enhancing platform technology from a clinical stage biotech company focusing on cancer immunotherapies.
• A long-established Chinese manufacturer specializing in canned fruits and natural beverages: corporate developments in the United States.
• A provider of modular bio-experiment as a service on semiconductor chips to accelerate bio-discovery by 1000 times: global patent portfolio management.
• Multiple artificial intelligence (AI)-driven drug development companies: general corporate, IP, services, BD and financing transactions.
• Eluminex Biosciences: general corporate, services and various licensing, collaboration and M&A transactions, including:
  • global exclusive license agreement with FibroGen, on biosynthetic cornea and other recombinant human collagen products;° and
  • acquisition of Zuretinol assets from Retinagenix °
• Emugen Therapeutics: general corporate, license, collaboration and financing transactions, including multiple rounds of financing and the in-licensing of blood-brain barrier-penetrant AAV capsid from Apertura Gene Therapy.
• A global biopharmaceutical company devoted to developing a portfolio of novel biological therapies for patients worldwide: general IP, BD transactions, and distribution matters.
• A publicly listed company that engages in the manufacture and sale of electrical equipment that includes telecommunications equipment, cloud computing equipment, precision tools and industrial robots: general corporate, corporate governance, IP, investment and financing, international trade, regulatory compliance, labor and employment, data privacy and cybersecurity, real estate, and white collar defense and investigations matters.
• A top-tier biotech company focused on genome engineering technology in the healthcare sector: out-licensing to a global, commercial-stage biotechnology company developing and manufacturing novel therapies.
• A company focusing on restoring epigenetic health: general corporate, IP, financing, immigration and technology transactions matters, including in-licensing from a patient-focused, research and development (R&D)-driven global biopharmaceutical company.
• The largest overseas Chinese food delivery platform: U.S. labor and employment, regulatory compliance and independent contractor matters.
• A healthcare focused investment firm leveraging the top-tier medical resource ecosystems and industrial platform across China and the United States: investment in the health care industry, including IP due diligence.
• A Singapore-based technology company operating at the forefront of the remote haptic communication technology industry: employment dispute resolution.
• A clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells: general corporate matters.
• A company engaged in the R&D of dry powder inhaler with comprehensive expertise in formulation development: global patent portfolio management and technology transactions.
• An innovative enterprise dedicated to the introduction and development of diabetes products and technologies, and providing full-course management services for diabetic patients: cross-border collaborations and related dispute resolution.
• A clinical-stage company developing first-in-class therapeutics for chronic liver disease and inflammation: BD transactions.
• A commercial‑stage biopharmaceutical company founded in 2017 that develops innovative cell therapies and biologics—particularly CAR‑T treatments—for hematological malignancies and autoimmune diseases, supported by fully integrated platforms spanning discovery through commercialization: IP opinions and cross-border academic licensing and BD transactions.
• A provider of maintenance and construction services supporting the mining and industrial sectors in Western Australia: real estate and digital assets transactions in the U.S.
• A leading generator set manufacturer founded in 2007: international trade matter and joint venture transaction.
• A leading comprehensive property service operator in Central China and well-known across the country: U.S. M&A transactions.
• China’s first home-grown, internationally credible, full-service e-commerce partner: U.S. capital markets and digital assets transactions.
• A gaming brand devoted to creating more customized premium keyboards and peripherals with endless possibilities: cross-border asset acquisitions.
• A leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto: investment in biopharmaceuticals, human therapeutics, medical devices, and diagnostics companies, including IP due diligence.
• An early‑stage venture capital firm based in Palo Alto that invests in deep‑technology companies, partnering with visionary founders to help build category‑defining businesses: Japan investment matters.
• Legend Capital: multiple investment transactions, including investments in (and IP due diligence of):
  • Nuwacell Biotechnologies;° and
  • N1 Life.°
• A China‑based biopharmaceutical company founded in 2016 that develops innovative immuno‑oncology therapeutics, including PD‑1 and proprietary agonist antibodies, to advance next‑generation cancer treatments: BD transactions in the U.S.
• An education-focused AI innovation company founded at Harvard that provides project‑based, mentorship‑driven programs to cultivate the next generation of AI‑literate students and future tech leaders: U.S. immigration matters.
• A nutrition products e-commerce company: trademark and FDA regulatory compliance matters.
• A biotechnology company focused on allogeneic CAR-T in cancers and autoimmune diseases: general corporate, IP, financing, labor and employment, and BD transactions matters.
• Moderna: multiple collaboration transactions related to gene editing technologies, including collaborations with:
  • Metagenomi;°
  • Life Edit;° and
  • Generation Bio.°
• Myrobalan Therapeutics: general corporate, global patent portfolio management, services and technology transactions, and financing matters, including:
  • $24 million Series A funding round;° and
  • $400,000 grant from ALS Association.°
• A company building AI-guided care pathways to support women navigating midlife health transitions with menopause: general corporate, global patent portfolio management, labor and employment, and immigration matters.
• A leader in the Chinese reflective sheeting sector: S. patent application and prosecution.
• A premier life science service provider that offers a broad spectrum of R&D and manufacturing service capabilities throughout the entire drug discovery, preclinical, clinical development, and commercialization process: international trade and regulatory compliance matters.
• An end-to-end CDMO offering services from drug discovery to commercialization with proactive strategies, professional solutions and efficient processes in CGT, antibody and recombinant protein drug, aiming to accelerate drug development for customers: capital markets matters.
• Palleon Pharmaceuticals: multiple collaboration agreements with Shanghai Henlius Biotech, Inc.°
• Qilu Pharmaceutical: various licensing and collaboration transactions, including the exclusive licensing agreement and strategic partnership with Arbutus to develop and commercialize AB-729 in mainland China, Hong Kong, Macau, and Taiwan.°
• A biomedical company dedicated to the independent research and development and industrialization of innovative drugs for bone and joints: general corporate, joint venture, and licensing transactions, including the in-licensing from a tier-one research university.
• A biotechnology company developing a generative‑AI‑driven platform to design superior mRNA therapeutics with enhanced stability and translational performance: corporate development in the United States.
• A pioneer of a unique modality of non-degrading molecular glues for targets previously considered intractable: various licensing and collaboration transactions.
• A bio-pharma company spun out from Stanford University and focusing on developing new therapeutics based on innovative drug delivery technologies to address unmet medical needs of human and companion animals: IP and technology transactions.
• A powerhouse of innovation and early-stage therapeutic R&D for neurological disorders and aging: general corporate matters.
• A clinical-stage pharmaceutical company specializing in developing pioneering therapies aimed at enhancing the expression of therapeutic genes within diseased cells: IP opinions.
• A New York–based hedge fund and investment adviser founded in 2019 that focuses on research‑driven investments in global healthcare and biotechnology companies: cross-border investment matters.
• Riboway Therapeutics: various asset acquisition, licensing, and collaboration transactions, including collaboration with a leading pharmaceutical company in the United States.
• A company focusing on the research of non-invasive brain-computer interface technology: general corporate, IP, financing, and distribution matters.
• One of the largest pharmaceutical companies in China: BD transactions.
• A company committed to developing first-in-class antibody drugs: general corporate, IP, services, university collaboration, and various BD transactions.
• A Swiss Basel-Area based bio-pharmaceutical company developing novel and neuro-rescuing therapies to treat and reverse retinal and central nerve neurodegenerative diseases: general corporate and financing matters.
• An innovative biotechnology company founded in 2021 that focuses on developing original therapeutics for central nervous system disorders: general corporate matters.
• A world-leading internet and technology company that develops innovative products and services to improve the quality of life of people around the world: various investment and acquisition matters.
• Triastek: multiple collaboration transactions, including with Eli Lilly and Company.°
• A leading independent integrated energy group: financing transactions and private placement of debt instruments.
• A New York–based biotechnology investment and advisory firm that accelerates life‑science innovation through cross‑border partnerships and strategic capital deployment: IP opinions.
• A global footwear brand introduced and embraced in the United States in 2020 that's dedicated to supporting everyday life with eco-friendly comfort and style: U.S. labor and employment and dispute resolution matters.
• An assistant professor at an NCI-designated comprehensive cancer center: general legal matters.
• A Chinese biotechnology company focusing on R&D of innovative mRNA drugs and adjuvants: IP opinions and BD transactions.
• A high-tech biotechnology company co-founded by overseas experts, returnee scientists and local Chinese pharmaceutical entrepreneurs: various licensing, collaboration and financing matters, including collaboration with and investment by a global, science-led, patient-focused pharmaceutical °
• A privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival: general corporate, IP, and licensing matters.°
• A biologically-targeted radiation therapy company focused on developing novel treatment to improve the lives of patients with difficult-to-treat cancers: various distribution, license, and collaboration transactions, including with South Korean and Japanese collaborators.°
• China’s largest government designated anesthetics developer and manufacturer: global BD transactions.
• A research‑driven biotech company founded in 2024 that focuses on medical R&D and cell technology development, offering services spanning technical research, consulting, and technology transfer: general corporate and corporate restructuring matters.
• An international pharmaceutical company driven by innovative research and development: U.S. capital markets and BD transactions dispute resolution matters.

°The above representations were handled by Dr. Cui prior to his joining Greenberg Traurig, LLP.

• Adjunct Faculty Member, The Chinese University of Hong Kong Faculty of Law, 2013-2016.
• Guest Lecturer, Santa Clara University School of Law, 2022-present.

• Listed, The Best Lawyers in America, "Ones to Watch," Technology Law, 2024
• Listed, The Legal 500 United States, Life Sciences, 2022-2023

• Member, The BayHelix Group, 2021-present
• Founding Member, Asia Society Northern California Tech Council, 2024-present
• Lifetime Member, Chinese Bioscience Association
• Lifetime Member, Sino-American Pharmaceutical Professionals Association
• Lifetime Member, Chinese American Biopharmaceutical Society